Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma
A series of ASCO Chapter Meetings and an on-demand CME-certified Webcourse.
Welcome to "Oncology Exchange: Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma." This CME-certified initiative is intended for community-based hematologic oncologists, hematologists, medical oncologists, and other clinicians involved in the care of patients with Hodgkin lymphoma (HL). A series of live CME-certified programs will be presented at selected ASCO State/Regional meetings throughout the US during 2014/2015, and an online CME-certified webcourse will be available in late 2014.
Several novel treatment strategies have recently been investigated in the management of relapsed/refractory HL. These treatments have shown clinical promise in patients who historically have had poor prognoses. This program will educate community clinicians on these recent advances in the management of patients with relapsed/refractory HL and will help clinicians incorporate evidence-based treatment recommendations to improve patient outcomes.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email firstname.lastname@example.org.
Calendars for Live Activities
Back to Top
A calendar of live events, as well as additional CME/CE-certified online activities, for this and other Oncology Exchange programming, can be found at: http://www.medscape.org/sites/advances/oncologyexchange.
Live Program Materials for Speakers and Administrators
Back to Top
I. Administrator Material
II. Speaker Material
Thank you for joining us as an expert speaker for the ASCO State/Regional meeting Series, "Oncology Exchange: Emerging Strategies in Newly Diagnosed and Relapsed/Refractory Hodgkin Lymphoma."
This orientation will familiarize you with the complete slide set, provide insight from the program steering committee, and address potential questions. During the audio lecture, the following key topics will be discussed:
Assess emerging frontline approaches for patients with Hodgkin lymphoma
Evaluate the efficacy and safety data for novel agents in patients with relapsed/refractory Hodgkin lymphoma
Discuss strategies to mitigate adverse effects to improve long-term survival in Hodgkin lymphoma
Transcript of Speaker Orientation Download (PDF)
Audio download of Speaker Orientation
CME-certified Program Slides
This version of the program slides has been CME-certified and these slides are to be used for this activity. Download (PowerPoint)
Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Jeremy Abramson, MD is Director of the Lymphoma Program and the Jon and Jo Ann Hagler Chair in Lymphoma at the Massachusetts General Hospital Cancer Center. He is also Assistant Professor of Medicine at Harvard Medical School. Dr. Abramson earned his medical degree from the Mount Sinai School of Medicine in New York City and a Master’s Degree in Medical Sciences from Harvard Medical School. He completed a residency in internal medicine at the Massachusetts General Hospital in Boston, followed by a fellowship in hematology and oncology at the Dana-Farber Cancer Institute.
Dr. Abramson’s clinical and research interests are in lymphoid malignancies, including Hodgkin lymphoma, non-Hodgkin lymphomas, and chronic lymphocytic leukemia. His research involves identifying new targets for therapy in lymphomas and lymphoid leukemias, and the design and conduct of clinical trials for new cancer therapies in these diseases. He is a member of the American Society of Hematology and American Society of Clinical Oncology, and a Fellow of the American College of Physicians. Dr. Abramson is the author of numerous papers and book chapters on lymphoma and lectures widely.
Anas Younes, MD
Chief of Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY
As a medical oncologist and Chief of Memorial Sloan-Kettering's Lymphoma Service, Anas Younes, MD works with his clinical and basic-science colleagues to accelerate the translation of recent scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin and non-Hodgkin lymphoma.
Dr. Younes joined Memorial Sloan-Kettering in 2013 with two decades of experience in treating and managing people with lymphoma, and with an extensive background in translational scientific research. He is particularly interested in developing novel targeted therapies and linking them to biomarkers (early markers) that can help match patients with the most effective and minimally toxic medicines.
Dr. Younes has served as the Principal Investigator of more than 60 clinical trials in patients with Hodgkin and non-Hodgkin lymphoma, including national and international multi-center studies. He has led the efforts toward developing the first FDA-approved targeted drug for the treatment of Hodgkin lymphoma in more than three decades.
Nationally, he has led the National Cancer Institute-funded Specialized Programs of Research Excellence (SPOREs) in lymphoma focused on developing novel treatment strategies for Hodgkin and non-Hodgkin lymphoma. He also serves on the Scientific Advisory Board of the Lymphoma Research Foundation, and is a member of the National Cancer Institute Lymphoma Steering Committee.